Ultragenyx is no longer the Angelman story the market spent two years pricing. The registrational Aspire study of apazunersen missed both the Bayley cognition primary and the multidomain responder secondary in early September, and the equity repriced from the mid-twenties to the mid-teens in a single session. What remains is a commercial rare-disease franchise that just booked its highest quarterly revenue on record, plus two first-in-disease gene therapy approvals that arrived on either side of that miss. The debate is whether that commercial book, stripped of the Angelman option, still supports a path to profitability, or whether the sold-royalty capital structure and launch execution risk leave too little residual value for common holders.
Crysvita still does most of the work. Second-quarter revenue reached $214 million, and the phosphate-regulating antibody contributed the large majority of that print. Product sales and royalty lines both grew, while combined research and selling costs barely moved. The operating loss narrowed, but non-cash interest on sold future Crysvita royalties continues to sit between the operating line and reported net loss. Cash and marketable securities stood at $436 million at mid-year against royalty-sale liabilities of $1,202 million. That capital structure is the reason a record commercial quarter still leaves the equity looking like a leveraged claim on future Crysvita cash and on whether two ultra-rare gene therapies convert into paid infusions.
Management still guides full-year revenue in a band that implies a second-half step-up from the existing book alone, and it still talks about profitability in the following calendar year. Those statements predate the Aspire miss and the two gene-therapy labels. The next several quarters resolve whether GENGLYCOS and FAYUVI find payers and treatment centers fast enough to matter, whether the promised expense reductions after Angelman actually show up in the cost base, and whether Crysvita's sold-royalty overhang leaves enough cash conversion to fund the launches without another large equity raise. The question is no longer whether Angelman re-rates the stock. It is whether a mid-teens price on a royalty-encumbered commercial book plus two unproven launches is the right clearing level for a company that just lost its largest pipeline option.